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Abstract
Treatment of neuromuscular diseases is still an unsolved problem. Evidence over the last years strongly indicates the
involvement of malformation and dysfunction of neuromuscular junctions in the development of such medical conditions.
Stabilization of NMJs thus seems to be a promising approach to attenuate the disease progression of muscle wasting
diseases. An important pathway for the formation and maintenance of NMJs is the agrin/Lrp4/MuSK pathway. Here we
demonstrate that the agrin biologic NT-1654 is capable of activating the agrin/Lrp4/MuSK system in vivo, leading to an
almost full reversal of the sarcopenia-like phenotype in neurotrypsin-overexpressing (SARCO) mice. We also show that
injection of NT-1654 accelerates muscle re-innervation after nerve crush. This report demonstrates that a systemically
administered agrin fragment has the potential to counteract the symptoms of neuromuscular disorders.
Citation: Hettwer S, Lin S, Kucsera S, Haubitz M, Oliveri F, et al. (2014) Injection of a Soluble Fragment of Neural Agrin (NT-1654) Considerably Improves the
Muscle Pathology Caused by the Disassembly of the Neuromuscular Junction. PLoS ONE 9(2): e88739. doi:10.1371/journal.pone.0088739
Editor: Lin Mei, Georgia Regents University, United States of America
Received November 4, 2013; Accepted January 10, 2014; Published February 10, 2014
Copyright:  2014 Hettwer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Swiss Commission for Technology and Innovation (CTI), project number 12887.1. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have the following interests. Stefan Hettwer, Stefan Kucsera, Monika Haubitz, Ruggero G. Fariello and Jan W. Vrijbloed are
employed by Neurotune AG, and Stefan Hettwer, Ruggero G. Fariello and Jan W. Vrijbloed are shareholders of Neurotune. Neurotune is owned by shareholders
and has interests to develop NT-1654 further to clinical applications. A patent application (PCT/EP2010/005372; US2012/0208765 A1) is pending with the title:
‘‘Modified agrin fragment capable of restoring muscle strength for use as a medicament’’. There are no further patents, products in development or marketed




Neuromuscular disorders are a group of mostly mono-genetic
diseases that affect the motor system. The cells involved can be
motor neurons, peripheral nerves or the muscle and they include
diseases such as spinal muscular atrophy (SMA), amyotrophic
lateral sclerosis (ALS), Charcot Marie Tooth (CMT) syndrome,
congenital myasthenic syndrome (CMS) or muscular dystrophies.
Several lines of evidence indicate that the malfunctioning of the
neuromuscular junction (NMJ) contributes to most if not all of
those diseases [1,2]. Besides these rather rare diseases, enhanced
muscle loss during ageing, called sarcopenia, has been shown to
also involve the disassembly of the NMJ [3–5]. Thus, a key
element of counteracting muscle atrophy might be the mainte-
nance of NMJs.
The formation and maintenance of NMJs is driven by the
agrin/Lrp4/MuSK pathway [6]. During development, the extra-
cellular matrix molecule agrin is released from the innervating
motor neuron to bind to its receptor Lrp4, which in turn activates
the receptor tyrosine kinase MuSK. The local activation of MuSK,
via the binding to the cytosolic adaptor molecule Dok-7, then
causes the formation of the postsynaptic apparatus at the site of
nerve-muscle contact [7,8]. NMJs start as small, pre-formed
plaques and mature from perforated plaques into final, fully
innervated pretzel-like structures [7]. One of the hallmarks of
those postsynaptic structures is the high concentration of
acetylcholine receptors (AChRs), which reaches a density of more
than 10,000 molecules/mm2 [9]. The function of agrin to assemble
the postsynapse can be reproduced in tissue culture as overnight
incubation of aneural myotubes with recombinant neural agrin
induces high-density AChR clusters [10]. The use of those assays
has shown that a short amino acid insert at the C-terminal end of
agrin (called z insert) is essential for this activity. The agrin gene
codes for a family of basal lamina proteins that differ in function
and distribution [11]. Splice site specific knock-out experiments in
mice have confirmed that the z-insert is indeed required for NMJs
to form in vivo [11,12].
The agrin/Lrp4/MuSK signaling pathway is essential for
survival as mice deficient for either agrin, Lrp4, MuSK or Dok-
7 die at birth because of respiratory failure [6,13–17]. Moreover,
mutations or auto-antibodies against the elements of the agrin/
Lrp4/MuSK pathway lead to myasthenia [18,19]. Thus, there is
compelling evidence that the agrin/Lrp4/MuSK pathway is also
essential for the maintenance of the NMJ suggesting that
manipulation of this pathway may be a promising way to
ameliorate the phenotype of neuromuscular disorders. Indeed,
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genetic elevation of MuSK signaling has recently been shown to
improve motor performance and to delay denervation in a mouse
model for ALS [20].
Recently, neurotrypsin has been identified to affect the agrin/
Lrp4/MuSK pathway. Neurotrypsin is a synaptic serine peptidase
that cleaves agrin at two specific sites and thus inactivates its
AChR clustering activity [21]. The cleavage products, C-terminal
agrin fragments (CAFs), are released into the circulation.
Interestingly, CAFs are elevated in a subset of sarcopenia patients
[22], suggesting that degradation of agrin at NMJs may contribute
to sarcopenia. Indeed, overexpression of neurotrypsin in motor
neurons in mice causes a sarcopenia-like phenotype characterized
by muscle weakness, fragmentation of NMJs, higher serum levels
of CAF and pathological abnormalities in the muscle, suggesting
that it can serve as a mouse model for precocious sarcopenia [23].
The mice are thus called SARCO mice. The phenotype of
SARCO mice can be fully reversed by overexpression of a
neurotrypsin-resistant version of agrin, suggesting that replenish-
ment of agrin might be an option in the treatment of sarcopenia.
In this study, we engineered a C-terminal fragment of mouse
agrin, termed NT-1654, which is neurotrypsin-resistant, highly
soluble and retains the AChR clustering activity. Here, we show
that this recombinant agrin, administrated by subcutaneous
injection, can stabilize the NMJs of SARCO mice and thus
ameliorate the phenotype. We also provide evidence that re-
innervation after sciatic nerve crush can be accelerated by NT-
1654.
Results
NT-1654 is protected from neurotrypsin cleavage and is
highly soluble
NT-1654 represents a 44 kDa fragment of the C-terminal end of
murine agrin. It contains the 8 amino acid insertion at the z-site
rendering it active for AChR clustering. To obtain a highly soluble
fragment, the y site did not contain the 4 amino acid heparin
binding site preventing the molecule to stick to the extracellular
matrix. With this modification, the protein was soluble to
concentrations of at least 100 mg/ml. To protect NT-1654 from
cleavage by neurotrypsin at the b-site (Fig. S1A), the lysine at
position P1 was mutated to alanine as described in [21]. Size
exclusion chromatography confirmed that NT-1654 is monomeric
(Fig. S1B). The protein could be purified to a high degree of
purity as judged by size exclusion chromatography and sypro ruby
staining on an SDS-PAGE gel (Fig S1C).
NT-1654 shows AChR clustering activity in vitro and in
vivo
The AChR clustering activity was tested in vitro in differentiated
mouse C2C12 myotubes. Upon administration of NT-1654 for
16 hours, AChRs formed aggregates on the myotubes in a dose-
dependent manner (Fig S2A). The EC50 of NT-1654 was 440 6
130 pM (Fig. 1A). This value is in the range of the activity
reported for the corresponding fragment (but containing the
heparin binding site) derived from chick agrin when tested on
primary chick myotubes [10]. A binding to full-length Lrp4
expressed in HEK293 cells could be demonstrated (Fig. S2 B-D).
To test whether NT-1654 would also induce AChR aggregates in
vivo, we next injected it subcutaneously for 6 consecutive days into
C57/Bl6 mice. To increase the expression of AChRs in the
muscle, one hind leg was denervated by cutting the sciatic nerve.
Mice were injected with PBS (Control), 10 mg/kg NT-1654 or
1 mg/kg NT-1654, starting immediately after denervation. Soleus
and extensor digitorum longus (EDL) muscles were stained with
Alexa555-labeled a-bungarotoxin to identify non-synaptic (ectop-
ic) AChR clusters induced by NT-1654. Examination of the
innervated leg showed that no or only few non-synaptic AChR
clusters were induced by NT-1654. In contrast, NT-1654 induced
numerous ectopic AChR clusters in the soleus and the EDL muscle
of the denervated leg, while no or only few clusters were observed
upon injection of PBS (Fig. 1B). There was no difference between
the two dosage groups. The ectopic AChR clusters were found
mainly at both distal ends of the soleus muscle whereas they
appeared near the endplate band in the EDL muscle. These
experiments show that NT-1654 has the expected AChR
aggregation activity both in vitro and in vivo. The potency of NT-
1654 in the AChR aggregation assay is very similar to that
reported for the corresponding fragment of chick agrin supporting
the conclusion that NT-1654 acts via activating the agrin/Lrp4/
MuSK signalling pathway.
NT-1654 ameliorates the weight and strength loss of
SARCO mice
To further test whether NT-1654 would be beneficial in
situations where the NMJ disassembles, we tested its function to
reverse the NMJ phenotype in SARCO mice. Because almost all
NMJs of the animals are severely affected and partially denervated
at postnatal day 8 (P8) [24], we started treatment at P8 and
continued until P30. Mice were injected daily with 10 mg/kg NT-
1654 s.c. (SARCO treated) or vehicle (PBS) alone (SARCO). The
results were compared with vehicle-injected, non-transgenic
littermates (Control). The weight of the mice was recorded every
day during the treatment. At the beginning of the dosing, SARCO
mice already had a small (0.5 gram) but significant weight deficit
compared to the Controls (Fig. 2A). Starting around P20,
SARCO mice significantly gained less weight compared to
Controls. At P30, the average weight of SARCO mice was only
80% of Controls. In contrast, NT-1654 treated SARCO mice
gained significantly more weight than vehicle-injected SARCO
mice starting at P20. From that day on, the weight gain curve was
parallel to the curve of Control animals and at P30, NT-1654
treated SARCO mice reached 94% of the weight of Controls.
At the last treatment day, grip strength of the fore limbs and
hind limbs was recorded. SARCO mice had significantly reduced
grip strength in their fore- and hindlimbs compared to Controls
(80% and 61%, respectively; Fig. 2B). In contrast, the fore limb
grip strength of NT-1654 treated SARCO mice was indistinguish-
able from Controls (104%) and the hind limb grip strength
reached 80% of Control levels, which is an almost 20%
enhancement compared to non-treated SARCO mice. These
experiments thus show that NT-1654 can significantly preserve
muscle force compared to the vehicle-treated SARCO mice.
NT-1654 restores NMJ structures in SARCO mice
To test whether NT-1654 has any effect on the fragmentation of
the NMJ [23], we next examined their structure at the end of the
treatment at P30. Whole mount preparations of soleus muscle were
used in which presynaptic structures were labelled by antibodies to
neurofilament and synaptophysin followed by Alexa-488-conju-
gated secondary antibodies. Postsynaptic AChRs were labelled
with Alexa-555-conjugated a-bungarotoxin. As illustrated in Fig
3A, NMJs of Control mice showed normal innervation and the
typical pretzel-like structure. NMJs of SARCO mice treated with
NT-1654 were almost indistinguishable from Controls. Only a
slight fragmentation within the synaptic gutter was observed. The
pretzel-like structure was clearly formed and each endplate was
properly innervated with little or no signs of denervation. In
contrast, NMJs of vehicle-treated SARCO mice appeared strongly
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fragmented and many of them were only partially innervated.
Some of the postsynapses were completely lost. In addition,
terminal sprouting of the presynaptic nerve was often observed.
Some ectopic clusters were detected as well in non-treated
SARCO mice, indicative of denervation.
To analyse the NMJ morphology quantitatively, the postsynapse
fragmentation was classified into five categories as illustrated in
Fig. S3. NMJs in soleus muscle of SARCO mice showed
fragmentation class 1–4 with the majority of the NMJs being in
class 3, whereas those of SARCO mice treated with NT-1654 were
mostly classified as class 1 (Fig. 3B). Approximately half of the
NMJs of SARCO mice showed terminal sprouting and this
number was strongly reduced to only 2.5% when treated with NT-
1654 (Fig. 3C). These results indicate that NMJs are more stable
in the NT-1654 treated SARCO mice.
Koelle staining, which detects the activity of acetylcholine
esterase of the diaphragm was also used to analyse the NMJs.
Diaphragms of control animals showed the typical endplate band
in the central region of the muscle fibers (Fig. S4). Individual
NMJs were strongly labelled and showed the classical pretzel-like
appearance. In contrast, NMJs of vehicle-treated SARCO mice
stained only weakly and appeared highly fragmented. As expected,
the endplate band was broadened. In contrast, NMJs of SARCO
mice that were treated with NT-1654 resembled wild-type NMJs.
The endplate band of treated SARCO mice appeared to be
broadened compared to the endplate band of Controls. The
overall endplate staining was not as strong as in Controls but
markedly improved compared to untreated SARCO mice. In
addition, the shape of the NMJs was virtually identical to that of
control NMJs with indications of perforations similar to Controls.
This result resembles the observations in soleus muscle, suggesting
that NT-1654 treatment of SARCO mice lead to postsynaptic
structures similar to those detected in WT animals.
Muscle fibers of NT-1654 treated SARCO mice resemble
the wild-type phenotype
It has been previously described that the number of muscle
fibers is reduced in SARCO mice compared to Controls [23]. At
P30, we also observed a 27% loss of fiber number in the soleus
muscles of SARCO mice. In contrast, the number of muscle fibers
was as a trend even 14% higher than in Controls when SARCO
mice were treated with NT-1654 (Fig. 4B).
During the course of the study it was also noted that SARCO
mice contained many hybrid fibers. Such hybrid fibers are defined
by the simultaneous expression of myosine heavy chains charac-
teristic of type I and type II fibers (Fig. 4A). In soleus muscle of
Control mice, hybrid fibers represented only 1% of all the fibers
with remainder being 31% type I and 68 % type II fibers (Fig. 4A,
B). SARCO mice showed a strong increase in hybrid fibers to
27.5% of the total fiber number (asterisks in Fig. 4A). Treatment
of SARCO mice with NT-1654 normalized the fiber type
distribution to Control levels (Fig. 4).
Mitochondrial changes and/or breakdown are key elements for
specific pathways inducing muscle atrophy [25]. To assess whether
there were also changes in mitochondrial function in SARCO
mice, we also stained for cytochrome C oxidase (COX). SARCO
mice displayed a massive reduction in COX staining, which was
again normalized by the treatment of the mice with NT-1654
(Fig. 4A). These results thus show that SARCO mice display
many of the hallmarks of sarcopenia and that the treatment of the
mice with NT-1654 is sufficient to normalize those hallmarks to
Control levels.
NMJ recovery after nerve crushing is enhanced by NT-
1654
As NT-1654 restores the NMJs of SARCO mice from
fragmentation and nerve sprouting, we next tested whether NT-
1654 would also be beneficial for NMJ re-innervation. To establish
the re-innervation model, the sciatic nerve of mice expressing YFP
under the control of the Thy1 promoter [26] was crushed. The
mice were treated either with PBS (Control) or with NT-1654
(10 mg/kg) by daily injection. Injection was started immediately
Figure 1. NT-1654 induces ectopic AChR clusters. A: Dose
response curve of AChR-aggregating activity of NT-1654 in vitro. NT
1654 was applied on C2C12 myotubes and induced AChR clusters at the
concentrations indicated in Fig. S2A. The area of AChR clusters per
myotube was measured and normalized to the area of the myotubes.
Percentage clustering activity was calculated by the mean value of 108,
36 and 12 nM to 100%. Data points represent mean6 standard error of
triplicate cultures with 10 myotube segments counted in each. The
curve was fitted to the data points with a sigmoidal regression. The EC50
was determined from the fit as 440 pM and indicated by the dotted
lines. B: NT-1654 induces ectopic AChR clustering in vivo. NT-1654
induced ectopic AChR clusters in 6-days denervated soleus and EDL
muscles. The ectopic AChR clusters were mainly present in the distal
ends of soleus muscle whereas they were mainly at the NMJ zone of EDL
muscle. No or only few clusters were observed upon injection of PBS.
There is no obvious difference between 10 mg/kg and 1 mg/kg groups.
Scale bar: 50 mm.
doi:10.1371/journal.pone.0088739.g001
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after surgery and continued up to the analysis after 14 days. To
examine the re-innervation of NMJs, the postsynaptic apparatus
was stained with Alexa-555-conjugated a-bungarotoxin and the
presynaptic nerve terminal was visualized by YFP expression in
motor neurons. As shown in Fig. 5A, postsynaptic and presynaptic
structures fully matched in soleus muscle in both groups, indicating
that the muscle was fully re-innervated after 14 days. In control
group, many NMJs were still multiply innervated and several of
the nerve terminals sprouted, indicating that NMJs were still in the
process of remodelling at this time point. Compared to Controls,
NMJs of mice injected with NT-1654 showed little nerve sprouting
(Fig. 5A). Quantification revealed a significant lowering of the
number of terminals with nerve sprouting upon NT-1654 injection
compared to Control. While 86% of the NMJs from Controls
showed terminal sprouting, this fraction was reduced to 66% in
NT-1654 treated animals (Fig. 5B). Among those NMJs with
nerve sprouting, the NT-1654-injected group also showed a
significantly lower number of sprouts than the PBS-injected group.
These results suggest that NT-1654 promotes directed nerve
growth or accelerates the process of NMJ remodelling during re-
innervation.
Discussion
Optimal functioning of the NMJ depends on the formation of
this highly complex structure at a specific site within the muscle
fiber and, once this has been achieved, on its continuous
maintenance. Both of these processes are governed by agrin
through its interaction with the Lrp4/MuSK system [4]. In
previous studies [23,24] it was demonstrated that elevated levels of
neurotrypsin produce deleterious effects on NMJs and muscles in
SARCO mice. Since NMJ dysfunction is involved in the
pathogenesis of many neuromuscular diseases [1,2], we tested
the hypothesis that a systemically delivered protein that retains the
signalling function of neural agrin and, in addition, is resistant to
cleavage by neurotrypsin may restore the proper communication
between motor neurons and muscle fibers. Such an improvement
of NMJ function was achieved by overexpression of a neuro-
trypsin-resistant full-length agrin in SARCO mice [23]. In that
study, muscle fiber pathologies and loss of grip strength were
restored to WT. Interestingly, this was not the case when WT
agrin was overexpressed in the SARCO mouse background. This
shows the importance of protecting the b-cleavage site of agrin
from the deleterious cleavage by neurotrypsin.
The biologic NT-1654 is a 44-kDa protein derived from the C-
terminal portion of agrin, which was engineered with the aim of
retaining the agonistic activity on the Lrp4/MuSK receptor
complex. This fragment does not contain any heparan sulphate
chains or any binding sites for laminin, heparin or integrin. These
structural binding elements were removed from the agrin molecule
in order to optimize NT-1654 for tissue penetration without losing
signalling activity. In addition, a site-specific mutation at the b-
cleavage site was introduced to prevent its breakdown by
neurotrypsin. The resulting molecule is monomeric, highly soluble
and stable and can be produced in quantities of up to 900 mg/L
from transiently transfected CHO-S cells, which are all highly
desirable pharmacological properties. We here show that NT-
1654 binds to Lrp4 and induces AChR clusters in C2C12 myotube
(Fig. S2). The EC50 in the AChR clustering assay is 440 pM (Fig.
1A), which is similar to the activity of the C45 fragment of chick
agrin [10], indicating that it has the activity of agrin and the action
is mediated by the agrin/Lrp4/MuSK signalling pathway. This is
confirmed by the formation of ectopic AChR clusters observed in
the denervated soleus and EDL muscles (Fig. 1B). The interesting
observation on the differential distribution of ectoptic AChR
clusters in both muscles may be caused by a differential expression
pattern of MuSK or another factor regulated by innervation,
which was reported by Punga et al [27] and Lin et al [28]. While
soleus is a ‘delayed synapsing’ (DeSyn) muscle, EDL is a ‘fast
synapsing’ (FaSyn) muscle. The in vivo experiment alsoindicates
that NT-1654 reaches muscles when it is injected subcutaneously.
We next tested whether NT-1654 is able to normalize the
altered morphology of the NMJs and to restore the muscle
function in SARCO mice. SARCO mice overexpress neurotrypsin
in motor neurons starting around P0 [29]. At P4, 50% of the
NMJs are partially disassembled and the nerve terminals start to
Figure 2. Weight chart and grip strength analysis of NT-1654 and vehicle treated SARCO mice. A: Weight recording of wild type
littermates (Control), SARCO mice treated with NT-1654 (SARCO treated) and vehicle treated SARCO mice (SARCO). Treatment started at P8 s.c. with
10 mg/kg per day and ended at P30. Weight was recorded every day before the next dose was applied. For control, littermates (SARCO and Control)
were simultaneously injected with PBS (vehicle). Starting at day 20, treated SARCO mice gain substantially more weight than the non-treated SARCO
littermates. From day 21 on, the difference in weight became significant (*, p,0.05). Number of animals: wt = 11; SARCO treated = 9, SARCO = 6. B:
Grip strength measurements of Controls, SARCO mice treated with NT-1654 and SARCO mice at P30, the last day of compound administration. Bars
represent mean values 6 standard deviation. Treated SARCO mice showed significantly increased grip strength compared to the non-treated SARCO
littermates. The forelimb strength reverted fully to Control level whereas the hindlimb strength was intermediate between wild type and SARCO
mice. Number of animals: wt = 11; SARCO treated = 9, SARCO = 6. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0088739.g002
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sprout. At P8, the dissolution of virtually all NMJs was observed
[24]. The alternation of NMJs is associated with muscle pathology
and diminished strength and performance [23]. We thus treated
the mice from P8 to P30. After 23 days of systematic
administration of NT-1654, the NMJ morphology of soleus and
diaphragm muscles of SARCO mice was strongly ameliorated,
showing nearly normal pretzel-like structure (Fig. 3, Fig. S4).
These results thus provide strong evidence that NT-1654 is
capable of rebuilding the disassembled NMJs. As NT-1654 is
active in the AChR clustering assay, its effect is likely mediated by
agrin/Lrp4/MuSK signalling. The ability of NT-1654 to reverse
the sarcopenia-like phenotype was also observed when examining
the fiber type composition of the soleus muscle. SARCO mice had
a profound increase of hybrid fibers to 27.5% of the total fiber
number (Fig 4).
Several lines of evidence indicate that hybrid fibers are
indicative of denervation [30]. NT-1654 reversed the hybrid
fibers to the normal segregation of type I and type II fibers when
administered systemically to SARCO mice, suggesting that it is
capable of enhancing innervation. In addition, we also observed
that the loss of muscle fibers due to disintegrated NMJs was
stopped and the energy metabolism was reverted back to normal
as indicated by the COX staining. This finding correlates with the
observations described by Powers at al., [25]: it is known that upon
induced muscle atrophy in humans, e.g. by immobilization,
mechanical ventilation or by denervation, mitochondrial physio-
logic changes and/or breakdown are key elements for specific
pathways inducing fiber atrophy. A possible involvement of the
agrin/Lrp4/MuSK pathway in the physiological changes of the
mitochondria has already been shown by [31] demonstrating
swollen and irregularly shaped mitochondria in humans suffering
from MuSK-dependent myasthenia gravis. Interestingly, this
phenotype can also be observed for the mitochondria of SARCO
mice ([24], refer to Fig 1K).
The improvements due to treatment of SARCO mice with NT-
1654 on biochemical and cellular level are also manifested in
physiological data: besides gaining weight similar to WT
littermates, NT-1654-treated animals showed improvement in
the grip strength (Fig. 2).
The beneficial effect of NT-1654 was confirmed in a SARCO
mouse independent nerve re-innervation model in Thy1/YFP
mice. 14 days after sciatic nerve crush, the NMJs of the NT-1654-
treated animals showed significantly fewer nerve sprouts than
those of the PBS-treated Control group. This suggests that the
process of re-innervation including nerve growth or the remod-
elling process after re-innervation has been accelerated by NT-
1654. It can be assumed that the induction of ectopic AChR
clusters could be one driving factor for accelerated re-innervation.
It has been shown by others [32] that the induction of ectopic
AChRs by agrin on the cultured myotubes leads to an accelerated
innervation when they are transplanted into mice.
The results also show that subcutaneously administered NT-
1654 reaches the target in vivo and exerts a beneficial function in
SARCO mice. This is the first report of a systemically treatment of
Figure 3. NMJ morphology of m. soleus of NT-1654 and vehicle treated SARCO mice. A: Confocal images of the NMJs in soleus muscle of
P30 Control or SARCO mice, treated or not treated with NT-1654 as indicated. The postsynaptic AChRs were stained with Alexa-555 conjugate a-
bungarotoxin (red) and the presynapse was stained with anti-neurofilament and synaptophysin antibodies (NF-Syn; green). The postsynapses were
highly fragmented, partially or completely lost in soleus muscle of SARCO mice. The postsynapses of NT-1654 treated SARCO mice resembled those in
Control mice, showing pretzel like structures and much less fragmentation. Scale bar: 50 mm. B: The postsynapses in Control mice showed
fragmentation class 0 (no fragmentation, for illustration see figure S3). The postsynapses of NT-1654 treated SARCO mice were mostly classified into
class 1, whereas the postsynapse of SARCO mice showed class 1-4 with a peak at class 3. C:Many NMJs of SARCO mice have terminal nerve sprouting,
which was dramatically reduced in the NT1654 treated SARCO mice. Data present mean6 standard deviation, n = 2 mice, 100 NMJs were counted in
each mouse.
doi:10.1371/journal.pone.0088739.g003
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a mouse model for neuromuscular disorders with an engineered
agrin fragment. Further investigations will reveal whether NT-
1654 has also a beneficial effect in other disease models. For
example, one could expect a beneficial effect of NT-1654 in
Agrnnmf380 mice, a model for congenital myasthenic syndrome
[33]. A treatment of mouse models for SMA or ALS may have
beneficial effects, although the primary cause of the disease cannot
be targeted by NT-1654. A strengthening of the NMJ may lead to
retrograde signalling that stabilizes the motor neuron. Straight in
line with this suggestion is the finding that moderate overexpres-
sion of MuSK in the SOD1/G93A ALS mouse model delayed the
disease onset and reduced the extent of muscle denervation and
thereby improved motor function [20]. A preservation of the NMJ
may prevent or delay the ‘‘dying back’’ of motor neurons in ALS
as discussed in detail elsewhere [34]. Future experiments will
reveal if NT-1654 can be of benefit in the treatment of human
neuromuscular diseases that directly or indirectly affect the agrin/
Lrp4/MuSK pathway. Whether age dependent sarcopenia might
be treatable by this molecule remains to be shown in correspond-
ing animal models, like the aged rat model [35]. As an
overexpression of neurotrypsin-resistant agrin in neurotrypsin
knock-out mice could not prevent signs of neuromuscular
degeneration at old age, only the subgroup of 30–40% sarcopenia
patients with neurotrypsin dependent sarcopenia [22] might be a
target. An important feature of NT-1654 is that properly
innervated muscle fibers are not affected as we could not observe
non-synaptic AChR clusters in fully innervated muscle, indicating
that partially denervated and fragmented NMJs are mainly
targeted. Thus, an adverse effect on healthy muscle is not
expected.
Material and Methods
Expression and purification of NT-1654
The C-terminal 44 kDa fragment of murine agrin (NT-1654)
was expressed using the pEAK8 vector (Edge biosystems). The
protein starts with L1519 (A2ASQ1 (AGRIN_MOUSE), Uni-
ProtKB/Swiss-Prot) and ends with the natural C-terminus of
agrin. The fragment contains the z-8 amino acid insert and in
addition the lysine to alanine mutation which renders the protein
protected against site specific neurotrypsin cleavage at the b-
cleavage site [36]. NT-1654 was transiently expressed in CHO-S
cells in suspension culture (Evitria, Switzerland) to a level of up to
900 mg/L. For purification, NT-1654 was precipitated from the
cell culture supernatant using 25% PEG 6000. The pellet was
resolved in J x PBS and subjected to hydroxyl-apatite chroma-
tography. NT-1654 was eluted in a potassium phosphate gradient
and the purification success was monitored by SDS-PAGE. Purity
of the protein was assessed by staining 5 mg of protein with Sypro
Ruby (Invitrogen) after SDS-PAGE followed by quantification
with a Stella Imaging system (Raytest) using the AIDA quantifi-
cation software. After purification, 54% of the protein could be
recovered with a purity .97% in endotoxin-free quality (,0.25
EU/mg). Endotoxin levels were determined using the Limulus
Amoebocyte Lysate PYROGENT Plus kit (Lonza). NT-1654
appeared as monomeric in size exclusion chromatography on a
superdex 200 10/300 GL column (GE healthcare) using PBS as
running buffer.
Lrp4 binding assay
HEK293 cells, grown to 80% confluency in a 35 mm dish were
transfected with 4 mg of an expression construct coding for Lrp4-
Figure 4. Fiber type distribution of m. soleus of NT-1654 and vehicle treated SARCO mice. A: Consecutive muscle cross sections of soleus
stained with myosine heavy chain (MHC) specific antibodies or cytochrome C oxidase (COX) staining as indicated. Control and treated SARCO mice
show clearly separated type I and II fibers. SARCO mice have a significantly increased amount of hybrid fibers (indicated with asterisks). Cytochrome C
staining of soleus sections shows a massive reduction of reactivity in SARCO mice which is reverted back to WT levels in treated SARCO mice. B:
Quantitative analysis of muscle fibers of soleus. Bars represent mean values 6 standard deviation. Control and treated SARCO mice have almost no
hybrid fibers and are indistinguishable from each other. Compared to treated ones, SARCO mice have significantly increased hybrid fibers. Type I
fibers are significantly decreased. The total fiber number in SARCO mice is also significantly decreased compared to treated animals. Number of
animals: wt = 3; SARCO treated = 5, SARCO = 3. * p,0.05; ** p,0.01. Scale bar: 100 mm.
doi:10.1371/journal.pone.0088739.g004
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myc (mouse full length Lrp4, cloned into pBluescript II KS+_myc
plasmid from E15.5 C57/Bl6 mouse embryo). After 48 hours
culture, cells were washed and incubated for 40 min at 37uC/5%
CO2 with 1 nM of NT-1639, i.e. a human version of NT-1654,
used for reasons of better detectability with the used antibody. The
recombinant C21 fragment of chick agrin [37] was used as a
positive control. The bound NT-1639 or C21 agrin were detected
by rabbit anti-mouse agrin antibody #204 [38] at 1:1000. The
expression of Lrp4 was detected by anti-Myc mAb at 1:1000 (Fig
S2B-D).
In vitro AChR clustering assay
150,000 C2C12 myoblasts were seeded on 35 mm tissue culture
dishes in proliferation medium (DMEM with 4.5 g/l glucose, L-
glutamine and sodium pyruvate; 10% Fetal bovine serum;
penicillin/streptomycin). Upon cells reaching confluence, the
medium was replaced with differentiation medium (DMEM low
glucose, L-glutamine and sodium pyruvate; 2% horse serum;
penicillin/streptomycin). After 2 to 3 days, myoblasts fused to form
myotubes. NT-1654, diluted in differentiation medium, was
subjected in different concentrations to the C2C12 myotubes for
16 hours. Myotubes were stained for AChRs by adding 500ml of
(1 mg/ml) rhodamine conjugated a-bungarotoxin (Invitrogen) to
the dish and incubation for 45-60min at 37uC. The dishes were
washed 3 times with 1–2 ml MEM and fixed with 95% ice cold
ethanol for 5min at –20uC. Ethanol was removed and evaporated
for 3 minutes until the dish was dry. The dishes were mounted
with Citifluor (Fig S2A). The area of AChR clusters per myotube
was measured and normalized to area of the myotubes. For the
calculation of the EC50, the mean value of AChR cluster area at
108 nM, 36 nM and 12 nM was set to 100% since the maximal
clustering activity was achieved at these concentrations.
Animal experiments
All animal experiments were performed on C57/Bl6 mice or
derivatives thereof in strict accordance with Swiss guidelines for
proper conduct of animal experiments and were approved by the
Veterinary Authorities (Kantonales Veterina¨ramt Basel, Kanto-
nales Veterina¨ramt Zu¨rich) of the Cantons Basel and Zurich
(Permission numbers 2593 for Basel and 18/2008; 31/2011 for
Zurich). All surgery was performed under ketamine (111 mg/kg)/
Zylaxine (22 mg/kg) for regular anesthesia and phenobarbital for
terminal anesthesia, and all efforts were made to minimize
suffering. To avoid inflammatory reactions, only endotoxin free
protein solutions were used in the experiments. Mice were kept in
Blue-Line cages on ‘‘abedd’’ bedding (both Indulab). A maximum
number of 5 mice were allowed per cage which was supplemented
with tissues and hiding places. Mice had continuous access to dry
pellets from Kliba Nafag and fresh drinking water. The night/day
cycle was 12h/12h and experiments were done predominantely at
times when mice were active.
In vivo AChR clustering assay
Mice were anesthetized with ketamine/Zylaxine and the sciatic
nerve of C57/Bl6 mice was cut on the left leg. The right leg was
sham operated for use as control. The mice were treated with PBS
(Control) or NT-1654 (10 mg/kg or 1 mg/kg) immediately after
denervation (once per day, s.c.). Six days after denervation, mice
were sacrificed and their muscles were harvested. Soleus and EDL
muscles were stained with Alexa555-conjugated a-bungarotoxin
(Invitrogen) to examine the formation of ectopic AChR clusters.
Transgenic mouse lines
The SARCO mice (B6.C3-Tg(PRSS12) 491 Zbz) expressing
transgenic human neurotrypsin under the Thy1.2 promoter, are
previously described by [24] and [29]. Genotyping was done as
described in [29]. A detailed investigation on this mouse line is
given in [23] (refer to Nto1 mouse line).
In order to examine the re-innervation process in the nerve
crushed muscle, the Thy1-YFP transgenic mice [39] were used.
The Thy1-YFP mice were purchased from the Jackson Laboratory
(Stock Number: 003709) and housed in the animal facility of
Biozentrum by backcrossing with C57/Bl6 mice.
In vivo compound administration
All mice were dosed with 1 mg/kg or 10 mg/kg NT-1654 s.c.
once a day for the time indicated. PBS was used as vehicle and was
administered to both SARCO mice and wild type littermates
(Control).
Figure 5. NMJ recovery after sciatic nerve crush. A: Confocal
images of the neuromuscular junctions (NMJs) in soleus muscle of Thy1-
YFP mice after 14 days sciatic nerve crushing, treated with NT-1654 or
PBS (Control) as indicated. The postsynaptic AChR was stained with
Alexa-555 conjugate a-bungarotoxin (red) and the presynapse was
visualized by the transgenic expression of YFP in motor neurons
(green). The NMJs in soleus muscle are fully re-innervated after 14 days
sciatic nerve crushing. The NMJs of NT-1654 treated mice showed
significantly less nerve sprouting than those treated with PBS (Control).
The number of nerve sprouting in each NMJ was counted and shown in
B. NMJs in the NT-1654 treated mice have significantly fewer events of
nerve sprouting and significantly fewer number of nerve sprouts than
those of Control mice. Data present mean 6 standard error, *: p,0.05
(two ways t-test), 100 NMJs were counted in each mouse, n = 3 mice,
scale bar: 50 mm.
doi:10.1371/journal.pone.0088739.g005
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Grip strength in the limbs
Grip strength was measured using a metal grip bar connected to a
tension spring balance (Columbus Instruments, Columbus OH). To
measure the strength in the fore limbs, the mouse was held by the
tail and allowed to grab the bar. Tomeasure the strength in the hind
limbs, the mouse was held by the tail and the fore limbs and then
allowed to grab the bar with the hind limbs. The measured strength
was the maximal force needed to pull the mouse gently away from
the bar. In each trial, every mouse was tested 5 times. Trials were
performed at P9, P10, P16, P19 and recording was done at P30.
NMJ stainings
Harvested muscles at the end of the treatment were prepared
for histopathological examination. Isolated soleus was injected with
2 mg/ml of Alexa555-conjugated a-bungarotoxin and incubated
for 30 min at room temperature. Muscles were washed 3 times
with PBS and fixed with 2% PFA in PBS for 10 min. After cutting
the muscle into bundles, they were permeabilized with 1% Triton
X-100 and incubated in blocking solution (5% horse serum and
0.2% Triton X-100 in PBS) for 2 hours at 4uC. The bundles were
then incubated with rabbit anti-neurofilament 200 (Sigma N4142,
1:10000) and rabbit anti-synaptophysin (DAKO A0010, 1:200) in
blocking solution over night at 4 uC. The bundles were washed
with blocking solution at 4uC. Then, they were incubated with
Alexa488 conjugated goat anti-rabbit/ antibodies for 2 hours at
4uC. The bundles were washed with blocking solution at 4uC and
mounted with Citifluor. Acetylcholine-esterase staining was done
with a modified Koelle reaction [40].
Morphological analysis of NMJs
To analyse the NMJ morphology quantitatively, the stained
NMJs were observed under the Leica DM 5000B fluorescence
microscope with 63x objective and classified into 5 categories
according to the class of postsynapse fragmentation (Fig S3). 0:
normal NMJ without fragmentation; 1: light fragmentation with
pretzel like postsynapse; 2: intermediate fragmentation; 3: severe
fragmentation, the pretzel like postsynapse could not be recog-
nized; 4: the postsynapse largely or completely disappeared. The
terminal sprouts of the NMJs were counted as well. 100 NMJs of
each mouse were counted.
Nerve crushing
The sciatic nerve of Thy1-YFP mice was crushed using a
forceps under ketamine/Zylaxine anesthesia. The mice were
treated with either PBS or NT-1654 (10 mg/kg) by daily injection
per s.c. immediately after operation for 14 days. To examine the
re-innervation of NMJs, postsynapse was stained with Alexa-555-
conjugated a-bungarotoxin and presynapse was visualized by YFP
expression in motor neurons. The stained muscle bundles were
observed under the Leica DM 5000B fluorescence microscope
with 63x objective. The number of the terminal sprouts of the
NMJs was counted.
Muscle fiber analysis
Mice were perfused under ketamine/Zylaxine anesthesia with
ice-cold 0.9% NaCl. The calf muscles of the leg were quickly
dissected as a package and frozen in isopentane cooled with liquid
nitrogen. Sections were cut at 12 mm in a cryostat at –20uC,
mounted on ‘‘superfrost plus’’ (Menzel) slides and stored at –20uC
until utilization. Staining of type I fibers was done with biotinylated
BA-D5 antibody, staining of type IIA fibers with SC-71 antibody as
described in [41]. For the determination of mitochondrial function
cytochrome C oxidase staining was used as described in [42].
Supporting Information
Figure S1 Domain structure and appearance of NT-
1654. A: Schematic drawing of full length agrin and NT-1654
(modified from [22]). NT-1654 consists of the LG2, EGF4 and
LG3 domains of agrin. At the y-site, no additional amino acids are
inserted while at the z-site 8 amino acids are inserted. The
neurotrypsin b-cleavage site is mutated at the P1 residue by
replacing the lysine by alanine. Neurotrypsin cleavage sites are
indicated as a-cleavage site and b-cleavage site. Heparan sulphate
glycan chain attachment sites are marked by lollipop chains,
glycosylation sites by lollipops. The three splice sites x, A/y, B/z
are indicated. NtA: N-terminal agrin domain; F: follistation
domains; LE: laminin EGF-like domains; S/T: serine/threonine
rich segments; SEA: sea urchin sperm protein, enterokinase, and
agrin domain; EG: EGF-like domain; LG: laminin globular like
domain; SS: signal sequence; TM: transmembrane segment. B:
Size exclusion chromatography revealed that NT-1654 is
monomeric. It elutes at the expected retention time. The elution
profile of the Biorad 151-1901 gel filtration standard is depicted in
red and the corresponding molecular weights of the standard
proteins are indicated above the curve. C: The protein could be
purified to a high degree of purity as judged by Sypro ruby
staining on an SDS-PAGE gel. 2 ug of protein were loaded.
(TIF)
Figure S2 Related to Figure 1: NT-1654 has AChR
clustering activity and directly binds to Lrp4. A: NT-
1654 induces ectopic AChR clustering in vitro, related to Fig. 1A.
C2C12 myotubes were subjected to various amounts of NT-1654
as indicated and stained with a-bungarotoxin to visualize clusters
of acetylcholine receptors (AChRs). The number and area of
AChR clusters were dose-dependent. The cluster area (percentage
of myotube area) was then used to determine the EC50 (see Fig.
1A). Scale bar: 50 mm. B: HEK293 cells were transfected with
Lrp4-myc and positive cells were detected by anti-myc antibodies
(green). Cell nuclei were visualized by DAPI staining. C:HEK 293
cells were transfected with Lrp4-myc and NT-1639 (a human
version of NT-1654) was added. NT-1639 that was bound to Lrp4
was detected by the 204 anti-agrin antibody (green). Cell nuclei
were visualized by DAPI staining. D: As a positive Control, a C21
fragment of human agrin is shown to bind to Lrp4 (green). Scale
bar: 20 mm.
(TIF)
Figure S3 Related to Figure 3: Categorization of post-
synapse fragmentation. In order to quantify the severity of
postsynapse fragmentation, we observed the NMJs under the Leica
DM 5000B fluorescence microscope with 63x objective. The
postsynaptic AChRs were stained with Alexa-555 conjugate a-
bungarotoxin (red) and the presynapse was stained with anti-
neurofilament and synaptophysin antibodies (NF-Syn; green).
Class 0: normal NMJ without fragmentation; class 1: light
fragmentation with pretzel like postsynapse; class 2: intermediate
fragmentation; class 3: severe fragmentation, the pretzel like
postsynapse could not be recognized; class 4: the postsynapse
largely or completely disappeared. Scale bar: 50 mm.
(TIF)
Figure S4 Acetycholine esterase activity on diaphragm
of NT-1654 and vehicle treated SARCO mice. Koelle-
staining of diaphragm of P30 mice as indicated. Left panels: 40 x,
right panels 200 x. The Koelle-staining visualizes the acetylcholine
esterase activity in the NMJs. NMJs of Control mice are stained
intense and are arranged in a distinct narrow endplate band. The
shape of the NMJs is roundish and some perforations can be
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observed. NMJs of SARCO mice are faintly stained and
fragmented. The endplate band is broader as in Controls,
comparable to that in treated SARCO mice. Staining in treated
SARCO mice is less intense but distinct. The shape of the NMJs is
mostly roundish with some perforations at the edge. Scale bar
given for 200 x magnitude: 50 mm.
(TIF)
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